Ozempic Doesn't Work for Every Form of Obesity. Palatin Technologies Is Targeting the Patients It Misses.
Most people at this point have heard of Ozempic. Far fewer have heard of the patients it does not help. For a meaningful subset of obese patients, GLP-1 drugs simply do not work, because the appetite circuit in their brain is broken in a way GLP-1 mechanisms cannot fix. Palatin Technologies (NYSE American: PTN) is among a small group of public companies developing drugs aimed directly at this population, and the category just received its biggest commercial validation yet.
The receptor in question is called MC4R, short for melanocortin-4 receptor. It sits in the hypothalamus, the brain's appetite control center. When MC4R signaling is disrupted, patients experience severe, unrelenting hunger that conventional weight-loss drugs do almost nothing to address.
There is already one approved MC4R drug: IMCIVREE (setmelanotide), made by Rhythm Pharmaceuticals (NASDAQ: RYTM), a company with a market capitalization of roughly $5.8 billion. Rhythm reported $60.1 million in IMCIVREE revenue for Q1 2026, up from $37.7 million a year earlier, and collected more than 150 U.S. patient start forms in the six weeks following a March 19, 2026, FDA approval that expanded the label into acquired hypothalamic obesity. The European Commission followed with marketing authorization on May 1, 2026. The category is real, growing, and reimbursed. What has not been solved is tolerability. IMCIVREE's most distinctive side effect is skin darkening (hyperpigmentation), caused by the drug activating a related receptor (MC1R) that controls pigmentation. Selectivity, hitting MC4R cleanly without activating MC1R, is what the next generation of MC4R drugs is competing on, and Rhythm itself is now developing two successor candidates of its own.
Palatin's most recent strategic decision is built around exactly that competition. The company had been positioning its oral candidate, PL7737, for an Investigational New Drug (IND) filing in the first half of 2026. On its May 13 Q3 FY2026 earnings call, management instead deliberately pushed the timeline back: the new IND target is the first half of 2027, but for a next-generation oral molecule that builds on what PL7737 taught them. As Carl Spana said on the call, rather than advance a compound that "may not be best in class," the company chose to divert resources into successor candidates whose internal preclinical profiles, per the company, show significantly improved MC4R selectivity, minimal MC1R activity, and increased potency, with what Palatin describes as the potential to eliminate hyperpigmentation entirely.
The asymmetry that decision sets up is what makes this story interesting. Hyperpigmentation is the single most distinctive limitation of the only approved MC4R drug, and Rhythm Pharmaceuticals, a roughly $5.8 billion company with an approved, growing product, has not meaningfully reduced that effect, let alone eliminated it. Palatin, which currently has an approximate $30 million market cap and remains preclinical, believes its next-generation oral MC4R candidates, designed with enhanced potency at MC4R and minimal activity at MC1R, could substantially reduce, and possibly eliminate hyperpigmentation.
The two companies are at very different stages, and clinical studies will ultimately determine whether the preclinical signal translates to humans. However, if successful, a cleaner and better tolerated MC4R drug in the same patient populations currently being commercialized by Rhythm, could represent a significant improvement and advancement for the category.
The nearer-term catalyst for Palatin is the second program. Its once-weekly injectable MC4R-selective peptide remains on track for an IND submission in the fourth quarter of calendar 2026, the regulatory step required to begin human trials and is now Palatin's lead clinical asset. Both programs target the same rare obesity disorders Rhythm has commercially validated: acquired hypothalamic obesity, Prader-Willi syndrome (a genetic condition characterized by extreme hunger from early childhood), and Bardet-Biedl syndrome. Whether early preclinical signals translate to humans is the question only clinical data can answer.
What is also unusual at this stage of development: revenue. Most pre-clinical small cap companies survive by repeatedly diluting shareholders. Palatin does not have to. A Boehringer Ingelheim partnership on melanocortin-based retinal-disease compounds delivered €7.5 million in 2025, and sublicensing the dry eye program PL9643 to Altanispac Labs added $3.8 million in January 2026. For the quarter ended March 31,2026, collaboration and license revenue reached $3.9 million against zero a year earlier. Net loss narrowed to $1.4 million from $4.8 million in the prior year. The company has indicated cash on hand can fund operations through June 30, 2027, past both IND milestones. Non-dilutive funding at this stage of a biotech's life is rare, and it materially de-risks the runway into Palatin's first clinical readout by reducing pressure to raise capital on someone else's terms.
Wall Street has begun to take notice. Three sell-side firms, Laidlaw, Lucid Capital Markets, and Alliance Global Partners, have initiated equity research coverage on PTN with ‘Buy’ ratings in the $45-$50 range. Further, Palatin will begin trading as a Nasdaq-listed company on May 29, 2026, and will continue to trade under the symbol “PTN.” Palatin’s common stock will continue to trade on the NYSE American until the market close on May 28, 2026.
Rhythm has shown that drugs targeting the brain's broken hunger switch can become a real commercial franchise. The front-runner has the head start and the revenue. The challenger has the freedom to design for what the market needs, and does not yet have. Palatin has just told investors which lane it chose to run in.
Read this Next >> New Phase 3 Data Reveals Why PolyPid's Approach to Surgical Infections Could Upend the Antibiotic Playbook
Recent News Highlights From Palatin (AMEX: PTN)
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from Palatin Technologies, Inc. (the "Issuer") for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.
